Plus Therapeutics Initiates SpectronRx Manufacturing for REYOBIQ Late-Stage Trial Readiness
Plus Therapeutics has initiated GMP manufacturing and technology transfer with SpectronRx at its Indiana facility under a Master Services Agreement, adding a second production site and securing Rhenium-186 supply from Telix Pharmaceuticals. This collaboration supports Plus Therapeutics’ 2026 goal for manufacturing scale-up to supply REYOBIQ clinical trials.
1. Partnership Agreement and Technology Transfer
Plus Therapeutics and SpectronRx have activated their Master Services Agreement to transfer REYOBIQ manufacturing processes, Rhenium-186 isotope processing methods, analytical assays, and regulatory expertise, establishing SpectronRx as a second GMP manufacturing site alongside Radiomedix.
2. Enhanced Manufacturing Infrastructure
SpectronRx’s Indiana facility will process Telix-supplied Rhenium-186 isotope and conduct GMP production of REYOBIQ within the same complex, consolidating isotope processing and drug formulation to improve coordination and streamline logistics.
3. Support for Late-Stage Clinical Supply
The partnership advances Plus Therapeutics toward its 2026 milestone for manufacturing scale-up, ensuring reliable supply of REYOBIQ for pivotal trials in recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.